VAERS 1743406
MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U002395
- Staat
- MI
- Alter
- -
- Geschlecht
- U
- Eingang
- 29.09.2021
- Impfdatum
- 21.09.2021
- Beginn
- 22.09.2021
- Tage bis Beginn
- 1,0
- Dosis
- UNK
- Route/Site
- - / -
Symptomtext
No additional AE reported; administration of MMR II and VARlVAX one day apart; This spontaneous report was received from an office manager referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported. On 21-SEP-2021, the patient was vaccinated with measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (rHA) (M-M-R II) injection, 0.5 milliliters (ml) (lot number T016195 which has been verified to be valid, expiration date reported as 30-MAY-2022, but upon internal validation established as 11-JUN-2022). On 22-SEP-2021, the patient was vaccinated with varicella virus vaccine live (Oka/Merck) (VARIVAX) injection, 0.5 ml (lot number U002395 which has been verified to be valid, expiration date reported and validated as 22-JAN-2023) (routes of administration and anatomical sites of injection were not reported) (inappropriate schedule of product administration). Both of the vaccines were administered as prophylaxis. No additional adverse events were reported in the patient.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -